Icotyde’s in; wave of switchers to oral psoriasis Protagonist?

AI Briefing

• – Protagonist Therapeutics gains FDA approval for oral psoriasis treatment Icotyde.
• – Icotyde to treat moderate to severe plaque psoriasis in adults and pediatric patients 12 and older.
• – Second product from Protagonist this year awaiting U.S. FDA approval.